Search Results

You are looking at 21 - 30 of 1,411 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, and Lisa A. Gurski

: December 10, 2018; Expiration date: December 10, 2019 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Thyroid Carcinoma Describe the rationale

Full access

Carcinoma of Unknown Primary: Focused Evaluation

Gauri R. Varadhachary

Poor universal agreement exists on the definition of carcinoma of unknown primary (CUP). Some ambiguity comes from the literature (or lack thereof) regarding what constitutes CUP syndromes, particularly because the workup for primary tumor

Full access

Selecting Targeted Therapies for Patients With Renal Cell Carcinoma

Elizabeth R. Plimack and Gary R. Hudes

metastatic clear cell RCC Describe second-line management of patients with metastatic clear cell RCC I n the past 5 years, 6 new agents were approved for the treatment of renal cell carcinoma (RCC). These can be broadly categorized into 2 groups: vascular

Full access

Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

A. Dimitrios Colevas

The global burden of squamous cell carcinoma of the head and neck (SCCHN) is substantial. In 2014, an estimated 55,000 new cases were diagnosed in the United States and 500,000 globally, accounting for approximately 5% of the domestic and 8% of

Full access

Anal Carcinoma Therapy: Can We Improve on 5-Fluorouracil/Mitomycin/Radiotherapy?

Yixing Jiang, Heath Mackley, Hua Cheng, and Jaffer A. Ajani

Squamous cell carcinoma of the anal canal is a rare disease, with incidence of approximately 1.6 per 100,000 based on SEER data from 2002 to 2006. 1 Over the past 2 decades, chemoradiation has become the cornerstone treatment in the management of

Full access

Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin

Urothelial carcinoma of the renal pelvis (UCRP) and the ureter is a rare disease, representing 5% of all urothelial malignancies. The incidence of UCRP in the general US population is estimated to be 1.15 per 100,000 person-years. 1 Although

Full access

Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma

Presented by: Rajiv Agarwal and Lea K. Matsuoka

Moderated by: Daniel B. Brown

Although surgical intervention is preferred for the management of hepatocellular carcinoma (HCC), tumor location, biology, and patient condition often dictate treatment decisions. At the NCCN 2022 Annual Conference, a panel of experts presented

Full access

Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis

Ju Dong Yang, Michael Luu, Amit G. Singal, Mazen Noureddin, Alexander Kuo, Walid S. Ayoub, Vinay Sundaram, Honore Kotler, Irene K. Kim, Tsuyoshi Todo, Georgios Voidonikolas, Todd V. Brennan, Kambiz Kosari, Andrew S. Klein, Andrew Hendifar, Shelly C. Lu, Nicholas N. Nissen, and Jun Gong

Background A unifocal hepatocellular carcinoma (HCC) measuring <2 cm (T1 HCC) without vascular invasion and extrahepatic metastasis is the tumor-related component of very early-stage disease. 1 This stage of HCC has a decreased likelihood of

Full access

Abiraterone in Metastatic Salivary Duct Carcinoma

Damien Urban, Danny Rischin, Christopher Angel, Ieta D’Costa, and Benjamin Solomon

Salivary duct carcinoma (SDC) is a rare cancer representing less than 10% of all salivary gland malignancies. 1 , 2 It is an aggressive tumour, with many patients succumbing to disseminated disease. 3 Given its rarity, no standard treatment

Full access

Hepatocellular Carcinoma: Updates to Screening and Diagnosis

Anne M. Covey

. Because the lesion is <10 mm, it is below the threshold for CT or MR. Thus, follow-up US in 3 to 6 months is recommended. (C) A hyperechoic liver mass >10 mm is suspicious for hepatocellular carcinoma and warrants further evaluation with multiphase CT or